Your browser is old and is not supported. Upgrade for better security.

Invest in Entelexo (YC W21)

Creating a new class of drugs to address incurable autoimmune diseases

Highlights

1
$553k raised to date, plus $310k on the same terms
2
CEO led the 1st clinical trials in the world evaluating exosomes as a treatment for autoimmune disease
3
Targeting 25M affected by immune-mediated diseases in US, equal to ~$150B in medical costs/year
4
Our intellectual property is patent-protected
5
Raising $2M for pre-clinical product development and IND enabling animal studies

Our Team

Milad Riazifar CEO
Exosome biologist with 10+ years of experience in exosome research and clinical development. Led the first clinical trial using exosomes in autoimmune disease to treat Type 1 Diabetes.
Todd Schurr COO
Multidisciplinary engineer with biomanufacturing experience. His expertise in cGMP manufacturing and process automation are key to streamlining the regulatory approval process.
CTO
Biomedical engineer with extensive experience in stem cell biology and protein engineering. His expertise in gene editing is key to the development of the technology platform.

Pitch


Downloads

Overview